RxDoctor Payments Data

Peter Weinstein, MD

Gastroenterology · Springfield, MANPI 1467410308

Payments from drug & device makers

$4,672in general payments, 2019–2025

Across 186 payments — averaging $25.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$571
  • Takeda Pharmaceuticals U.S.A., Inc.$455
  • Phathom Pharmaceuticals, Inc.$396
  • Boston Scientific$312
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$267
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,664100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,672 in reported general payments places this provider in the 65th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$170,493
Medicare patients
645
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$324,264
Humira(Cf) PenAdalimumab17$109,469
RinvoqUpadacitinib13$83,714
LinzessLinaclotide26$17,763
TrulancePlecanatide17$11,402
Mesalamine15$8,388
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl436$6,992
ClenpiqSod Picosulf/Mag Ox/Citric Ac35$6,051
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C41$5,769
Ursodiol22$5,735
Omeprazole202$2,373
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl52$887
Pantoprazole Sodium54$879
Dicyclomine Hcl42$745
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg29$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$571$324,26412 claims
AbbVieRinvoq, Linzess$1,574$101,47839 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Plenvu$267$17,17258 claims
Ferring Pharmaceuticals Inc.Clenpiq$37$6,05135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →